Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study).

CapOx esophagogastric cancer nab-paclitaxel phase I clinical trial stromal cells

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
14 Jun 2019
Historique:
received: 26 04 2019
revised: 31 05 2019
accepted: 11 06 2019
entrez: 19 6 2019
pubmed: 19 6 2019
medline: 19 6 2019
Statut: epublish

Résumé

First-line triplet chemotherapy including a taxane may prolong survival in patients with metastatic esophagogastric cancer. The added toxicity of the taxane might be minimized by using nab-paclitaxel. The aim of this phase I study was to determine the feasibility of combining nab-paclitaxel with the standard of care in the Netherlands, capecitabine and oxaliplatin (CapOx). Patients with metastatic esophagogastric adenocarcinoma received oxaliplatin 65 mg/m

Identifiants

DOI: 10.3390/cancers11060827 PMID: 31207904 PMC: PMC6627561
pubmed: 31207904
pii: cancers11060827
doi: 10.3390/cancers11060827
pmc: PMC6627561
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Celgene
ID : IIT2264019(XXX)

Références

Nat Med. 1999 Jun;5(6):662-8
pubmed: 10371505
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76
pubmed: 11181773
Semin Radiat Oncol. 2004 Jul;14(3):198-206
pubmed: 15254862
Eur J Cancer. 2005 May;41(8):1135-9
pubmed: 15911236
Eur J Cancer. 2005 Aug;41(12):1690-6
pubmed: 16043346
J Clin Oncol. 2005 Aug 20;23(24):5660-7
pubmed: 16110025
J Clin Oncol. 2006 Nov 1;24(31):4991-7
pubmed: 17075117
J Clin Oncol. 2007 Aug 1;25(22):3217-23
pubmed: 17664469
N Engl J Med. 2008 Jan 3;358(1):36-46
pubmed: 18172173
J Clin Oncol. 2008 Mar 20;26(9):1435-42
pubmed: 18349393
Ann Oncol. 2008 Aug;19(8):1450-7
pubmed: 18558665
Ann Oncol. 2009 Mar;20(3):449-53
pubmed: 19087987
Ann Oncol. 2010 Jan;21(1):71-7
pubmed: 19605504
Cancer Cell. 2009 Dec 8;16(6):455-7
pubmed: 19962663
Science. 2009 Nov 27;326(5957):1216-9
pubmed: 19965464
Eur J Cancer. 2010 Mar;46(4):720-8
pubmed: 20044247
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Br J Cancer. 2010 Oct 26;103(9):1343-8
pubmed: 20924378
Eur J Cancer. 2011 May;47(8):1146-51
pubmed: 21269822
Eur J Cancer. 2012 Mar;48(4):518-26
pubmed: 22243774
Int J Clin Oncol. 2013 Jun;18(3):510-6
pubmed: 22669361
Gut. 2013 Aug;62(8):1100-11
pubmed: 22735568
Eur J Cancer. 2013 Mar;49(4):835-42
pubmed: 23063354
PLoS One. 2012;7(12):e51862
pubmed: 23251644
Gastric Cancer. 2014 Jan;17(1):181-7
pubmed: 23455717
Oncologist. 2014 Jul;19(7):712-9
pubmed: 24951609
J Pathol. 2015 Feb;235(3):466-77
pubmed: 25345775
Ann Oncol. 2015 Jan;26(1):149-56
pubmed: 25416687
Cancer Metastasis Rev. 2015 Mar;34(1):97-114
pubmed: 25566685
Gastric Cancer. 2016 Jan;19(1):234-44
pubmed: 25604851
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
J Clin Oncol. 2015 Nov 20;33(33):3874-9
pubmed: 26438119
J Clin Oncol. 2016 Feb 10;34(5):443-51
pubmed: 26628478
Am J Clin Oncol. 2018 Apr;41(4):321-325
pubmed: 26908161
J Clin Oncol. 2016 Aug 10;34(23):2728-35
pubmed: 27325864
Cancer Metastasis Rev. 2016 Sep;35(3):439-56
pubmed: 27417221
J Natl Cancer Inst. 2016 Aug 30;108(10):
pubmed: 27576566
JAMA Oncol. 2017 May 1;3(5):620-627
pubmed: 27918764
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287
pubmed: 28404157
Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064
pubmed: 28850174
Ann Oncol. 2017 Sep 1;28(9):2142-2148
pubmed: 28911091
BMC Cancer. 2017 Dec 8;17(1):837
pubmed: 29221445
J Cell Physiol. 2018 Sep;233(9):6359-6369
pubmed: 29334123
Dig Liver Dis. 2018 Apr;50(4):408-410
pubmed: 29409778
Front Cell Dev Biol. 2018 May 08;6:48
pubmed: 29868579
Oncotarget. 2018 Jul 3;9(51):29820-29841
pubmed: 30038723
Oncogenesis. 2018 Nov 16;7(11):87
pubmed: 30442938
Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2237-2242
pubmed: 30670657
Curr Opin Clin Nutr Metab Care. 2019 Jul;22(4):250-263
pubmed: 31116106
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390

Auteurs

Sandor Schokker (S)

Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. s.schokker@amc.uva.nl.
Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. s.schokker@amc.uva.nl.
ORCID: 0000-0003-3180-7790

Stephanie O van der Woude (SO)

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. s.o.vanderwoude@amsterdamumc.nl.

Jessy Joy van Kleef (JJ)

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. j.j.vankleef@amsterdamumc.nl.
ORCID: 0000-0002-9432-7199

Daan J van Zoen (DJ)

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. d.j.vanzoen@amc.uva.nl.

Martijn G H van Oijen (MGH)

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. m.g.vanoijen@amsterdamumc.nl.

Banafsche Mearadji (B)

Department of Radiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. b.mearadji@amc.uva.nl.

Ludo F M Beenen (LFM)

Department of Radiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. l.f.beenen@amc.uva.nl.
ORCID: 0000-0001-9204-1026

Charlotte I Stroes (CI)

Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. c.i.stroes@amsterdamumc.nl.
Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. c.i.stroes@amsterdamumc.nl.

Cynthia Waasdorp (C)

Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. c.waasdorp@amc.uva.nl.

R Aarti Jibodh (RA)

Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. r.a.jibodh@amc.uva.nl.

Aafke Creemers (A)

Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. a.creemers@amsterdamumc.nl.

Sybren L Meijer (SL)

Department of Pathology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. s.l.meijer@amc.uva.nl.

Gerrit K J Hooijer (GKJ)

Department of Pathology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. g.k.hooijer@amc.uva.nl.

Cornelis J A Punt (CJA)

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. c.punt@amsterdamumc.nl.

Maarten F Bijlsma (MF)

Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. m.f.bijlsma@amc.uva.nl.
ORCID: 0000-0001-6627-3229

Hanneke W M van Laarhoven (HWM)

Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. h.vanlaarhoven@amsterdamumc.nl.
Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. h.vanlaarhoven@amsterdamumc.nl.

Classifications MeSH